

1957

# The Use of Fluorescent Antibody and Isolated Chromosomes in the Study of Lupus Erythematosus Serum

Melville P. Roberts Jr.  
*Yale University*

Follow this and additional works at: <http://elischolar.library.yale.edu/ymtdl>

---

## Recommended Citation

Roberts, Melville P. Jr., "The Use of Fluorescent Antibody and Isolated Chromosomes in the Study of Lupus Erythematosus Serum" (1957). *Yale Medicine Thesis Digital Library*. 3076.  
<http://elischolar.library.yale.edu/ymtdl/3076>

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [elischolar@yale.edu](mailto:elischolar@yale.edu).

T113  
+Y12  
2105

YALE UNIVERSITY LIBRARY



3 9002 06712 1658

FLOURESCENT ANIBODY IN THE STUDY OF  
LUPUS ERYTHEMATOSUS SERUM

MELVILLE P. ROBERTS JR

1957

MUDD  
LIBRARY  
Medical

YALE



MEDICAL LIBRARY









THE USE OF FLUORESCENT ANTIBODY AND ISOLATED  
CHROMOSOMES IN THE STUDY OF LUPUS ERYTHEMATOSUS  
SERUM

Melville P. Roberts, Jr.

Presented to the Faculty of the School  
of Medicine of Yale University in candidacy  
for the degree of Doctor of Medicine

1957






T113  
Y12  
R105

## Acknowledgement

To doctors George J. Friou and Philip B. Cowles I express my deepest appreciation. Without their constant enthusiastic aid and counsel this thesis would not have been possible.

Many thanks also to Carmella Santarsiaro for her most helpful technical assistance.



Digitized by the Internet Archive  
in 2017 with funding from  
The National Endowment for the Humanities and the Arcadia Fund

<https://archive.org/details/flourescentantib00robe>

## INDEX

<u>Introduction</u>	1
<u>The L.E. Cell</u>	3
<u>The L.E. Cell Phenomenon</u>	4
<u>The L.E. Cell Factor</u>	5
<u>Methods and Materials</u>	9
Isolation of Chromosomes	13
Fluorescent Antibody	15
Staining Procedure	16
<u>Results</u>	17
<u>Summary</u>	20

Table 1

1990-1995

1990	1.2
1991	1.5
1992	1.8
1993	2.1
1994	2.4
1995	2.7

Source: Author's calculations

Notes: All figures in percent

1. The sample period is 1990-1995

1990  
1991  
1992

1993

1994

INTRODUCTION

From the time when the lupus erythematosus cell was first described by Hargraves, Richmond, and Morton<sup>1</sup> there has been much speculation as to what factors are responsible for its production. Initially it was believed that the L.E. cell was pathognomonic of lupus erythematosus.<sup>2</sup> As the phenomenon became better known, however, various workers reported the L.E. cell phenomenon in other diseases.<sup>3,4,5,6</sup>

Early investigators of the L.E. cell hypothesized that the phenomenon was due to a factor present in the blood plasma. This theory was later borne out by experiments which demonstrated that the L.E. factor was present in the gamma globulin fraction of the plasma proteins.<sup>7</sup>

Miescher has demonstrated that absorption of lupus serum with isolated nuclei results in removal or destruction of the L.E. factor.<sup>8</sup> Very recently the fluorescent antibody technique has been applied to this problem. In the first report of such studies it was shown in vitro that a globulin factor of lupus serum adheres to nuclei in sections of tissue.<sup>9</sup> Further studies revealed that nucleoprotein might be the nuclear factor involved in this reaction.<sup>10</sup> The investigation to be reported here is an attempt



2.

to further elucidate this problem through the use of isolated chromosomes and the fluorescent antibody technique.





The L.E. Cell

The L.E. cell was first described by Hargraves, Richmond, and Morton in 1948. They often noted that in the bone marrow of patients with lupus erythematosus a peculiar cell was to be found. "This cell undoubtedly represents a process which is going on in such bone marrows and is the end result of one of two things: either phagocytoses of free nuclear material with a resulting round vacuole containing this partially digested and lysed nuclear material or, second, an actual autolysis of one or more lobes of the nucleus of the involved cell so that it presents essentially the same appearance as the one which has phagocytized nuclear material."<sup>1</sup> Hargraves, Richmond, and Morton concluded their description of the L.E. cell by suggesting that the finding of L.E. cells in a patients' bone marrow might be of some help in diagnosing lupus erythematosus. Shortly after the publication of the original description other workers reported finding such cells in patients with systemic lupus erythematosus.<sup>11</sup>

For a time it was believed that these peculiar cells were pathognomonic of disseminated lupus erythematosus.<sup>2,16</sup> Later investigations, however, demonstrated that this was not true. L.E. cells have been found in association with the "collagen diseases" and with drug hypersensitivity reactions



as well. In particular, L.E. cells have been described in periarteritis nodosa,<sup>3</sup> penicillin<sup>4</sup> and hydantoin<sup>5</sup> hypersensitivity, as well as during hydralazine therapy.<sup>6</sup>

#### The L.E. Cell Phenomenon

Until 1949 the only reliable way in which L.E. cells could be demonstrated was by aspiration and examination of bone marrow. If the bone marrow was hypoplastic or the patient too ill for sternal puncture this method of investigation had obvious disadvantages. In 1949 Haserick and Bortz found that L.E. cells could be produced by adding plasma taken from patients with acute disseminated lupus erythematosus to heparinized normal bone marrow.<sup>12,13</sup> It was also noted that leukocyte clumping was induced.

The discovery of the L.E. cell phenomenon was very important because it shed light on a few basic principles concerning the L.E. cell. First of all, it revealed that the plasma of patients with acute disseminated lupus erythematosus contained a factor responsible for the formation of the L.E. cell. Secondly, it also became apparent that the production of the L.E. cell was a secondary rather than a primary phenomenon.



The L.E. Cell Factor

Now that it had been established that the formation of L.E. cells was due to the presence of a factor in the plasma the next step was to identify the substance. A few facts were already known concerning its nature. Firstly, it was stable for periods of at least as long as six months provided that the plasma was kept sterile.<sup>11</sup> It was destroyed by heating the plasma to 65° C. Para-aminobenzoic acid seemed to inhibit the activity of the factor, although this may have been due to a direct effect of the acid on the bone marrow. The factor could not be detected in patients during a remission but only during the acute phase of the disseminated lupus erythematosus. The factor could not be found in patients suffering from rheumatic fever, subacute or chronic lupus erythematosus, cirrhosis, rheumatoid arthritis, scleroderma, dermatomyositis, or periarteritis nodosa.<sup>14</sup> Later workers, however, were able to demonstrate the L.E. phenomenon in some of these conditions and in other diseases as well.

In order to identify which portion of the blood plasma contained the L.E. factor, Haserick, Lewis, and Bortz in 1950, employed fractionation by the Tiselius electrophoretic technique.<sup>7</sup> These investigators divided plasma from a patient with acute



disseminated lupus erythematosus into several fractions: 1) albumin, (3.5 mg.); 2) albumin, alpha and beta globulin (12 mg.); 3) gamma globulin (2 mg.); and 4) gamma globulin and fibrinogen (4.8 mg.). Then, by adding each fraction to normal bone marrow and noting L.E. cell formation, it was determined that only the gamma globulin fraction contained the L.E. factor.

In an attempt to prove that the L.E. factor is an immunologically distinct component of gamma globulin, Haserick and Lewis conducted an ingenious experiment.<sup>15</sup> By electrophoresis they first separated the gamma globulin fraction from the plasma obtained from a patient suffering with acute disseminated lupus erythematosus. An antiserum against this fraction was then produced by repeated injections of the gamma globulin into rabbits. A control rabbit antiserum against normal human gamma globulin was also produced by the same method. Next, the investigators took a quantity of human L.E. gamma globulin and divided it into two portions. To one portion was added the antiserum to L.E. gamma globulin, and to the other was added the control antiserum. In both portions a precipitate formed and was removed by centrifugation. The supernatant





fluid from each portion was then added to bone marrow preparations which were subsequently examined for L.E. cell formation. The L.E. gamma globulin to which had been added the antiserum to normal human gamma globulin caused the production of L.E. cells. On the other hand, the L.E. gamma globulin to which had been added antiserum to L.E. gamma globulin was unable to induce L.E. cell formation.

Although the above experiment has been widely accepted as proof that the L.E. factor in gamma globulin is a distinct immunological entity, the possibility of incomplete precipitation remains as an alternative explanation.

At this point it would be appropriate to list the salient properties of the L.E. factor as revealed by past investigations.

1. The L.E. factor is contained in the gamma globulin fraction of the blood plasma.
2. The presence of the factor can be demonstrated by adding L.E. plasma to a normal bone marrow preparation thus producing L.E. cell formation (this is referred to as the L.E. cell phenomenon).



3. The L.E. factor is probably a distinct immunological entity.
4. The L.E. factor has been found in diseases other than acute disseminated lupus erythematosus, notably in drug hypersensitivities and in some of the other "collagen diseases."
5. The factor induces nucleolysis and nucleophagocytosis with the resulting production of an L.E. cell.



Methods and MaterialsThe Fluorescent Dye Labeled Antibody Technique

The technique of labeling an antibody with a dye so that the complex resulting from the combination of this labeled antibody with its specific antigen could be visualized was first successfully accomplished by Reiner in 1930.<sup>17</sup> Reiner was able to chemically combine antipneumococcus I and II antibodies and atoxyl-azo dyes. He noted that the dye-antiserum complex had the same agglutinative titre as the original antiserum and that its mouse-protection activity was unaltered.

Marrack, in 1934, reacted diazotized benzidine-azo-R-salt with anti-typhoid and anti-cholera sera and then demonstrated that the homologous organisms were stained pink by the dye-labeled antibodies.<sup>18</sup> In order to prove that the dye-typhoid antibody complex was immunologically identical with the original typhoid antiserum he performed a rather clever experiment. He mixed ordinary cholera antiserum with an equal amount of the typhoid antiserum-dye complex. To one-half of this mixture he then added typhoid bacilli. The cholera vibrios were agglutinated but unstained. The typhoid bacilli, on the other hand, were not only agglutinated but also stained red. This simple procedure demonstrated



that the typhoid antiserum was immunologically unaltered by the dye conjugation.

Coons, Creech, and Jones were the first to combine an antiserum with a fluorescent moiety and thus render the resulting antigen-antibody complex fluorescent in ultraviolet light.<sup>19</sup> In 1941 they prepared a B-anthryl-carbamido derivative of anti-pneumococcus III rabbit serum which produced a faint blue fluorescence in daylight and an intense blue fluorescence in ultraviolet light. At the same time it was demonstrated that the conjugation procedure in no way interfered with the specific reactivity of the antiserum.

In 1942, Coons and his group showed that a fluorescein-carbamido-pneumococcal III antiserum could specifically stain tissues from a mouse infected with type III pneumococcus.<sup>20</sup> In 1950, Coons and Kaplan reported improvements in the synthesis of fluorescein isocyanate which had been first accomplished by Bogert and Wright<sup>21,22</sup> and modified later by Coons, Breech, Jones, and Berliner.<sup>23</sup> At the same time they also defined the optimum conditions for combining the fluorescent isocyanate dye with protein materials. They then conjugated antipneumococcal rabbit serum, type III, with fluorescein





isocyanate II by their improved technique. The fluorescent dye-labeled antipneumococcal antiserum was then successfully used to locate pneumococcal polysaccharides in the tissues of mice.<sup>24</sup>

Many other investigators have employed the Coons technique of combining antiserum with the fluorescent dye, fluorescein isocyanate, in order to locate a specific antigen in animal tissues. Conjugates have been prepared to identify the capsular polysaccharide of Friedlander's bacillus,<sup>25</sup> mumps virus,<sup>26</sup> plasma proteins,<sup>27</sup> *Endamoeba histolytica*,<sup>28</sup> and many other antigenic substances.

Figure I is a diagrammatic representation of the Coons dye labeled antibody reactions.

A slightly more complex, but just as useful technique is often employed. If, for example, one is dealing with an antigen, the antibody to which is located in the gamma globulin fraction of human serum it is not necessary to make up a specific dye-antibody conjugate against the antigen. Instead, a fluorescent antibody is made up against human gamma globulin. Then, any antibody from the gamma globulin which combines with the antigen will, in turn, also combine with the fluorescent antibody against the




Figure I


a. The antibody with its specific receptor, 1,



is chemically combined with a fluorescent dye, fluorescein isocyanate.



b. To identify the specific antigen the dye-antibody conjugate is then added:





human gamma globulin. Thus the original antigen is labeled by a two stage process (figure II).

In the work to be reported here, the techniques just described were employed in attempts to demonstrate that a factor in lupus serum is capable of combining with some material present in isolated chromosomes.


#### The Isolation of Chromosomes

The chromosomes were isolated from chicken erythrocytes, which are nucleated. The method used was that of Mirsky and Ris.<sup>29</sup> Blood was obtained by cutting the chicken's throat and collecting it in a bottle with oxalate. The blood (20 ml.) was then centrifuged for 15 minutes at 5000 rpm. at a temperature of one degree centigrade. The buffy coat and plasma were decanted and the remaining red cells washed three times in 0.14 M NaCl. Next, the washed cells were mixed with approximately 100 ml. of 0.14 M NaCl, placed in a Waring blender, and beaten for 20 minutes. Ice was packed around the outside of the blender so that the contents could be kept cool. The resulting mixture was centrifuged for 15 minutes at




FIGURE II


a. Antibody with its specific receptor 1, and its species specific receptor, 2.




b. The antibody against the gamma globulin species specific receptor of antibody A is combined with a dye, fluorescein isocyanate.



c. To identify the specific antigen, antibody A (non-fluorescent) is first added.



d. Next, the dye-antibody B conjugate which is an antibody against the species specific receptor of antibody A is added.







5000 rpm, the red supernatant fluid poured off, and the precipitate, consisting of chromosomes which have been removed from the erythrocyte nucleus, then washed with saline. All solutions were kept at approximately one degree centigrade during the entire process.

To verify the presence of chromosomes in the precipitate, smears were made on slides and stained by the Fuelgen method which is specific for nucleoprotein. Chromosomes with their characteristic morphology, as described by Mirsky and Ris, could be identified.<sup>26</sup>

#### Source of Human Sera

Serum was obtained from patients who had been diagnosed clinically as suffering from lupus erythematosus. The sera used for these tests was known to contain the factor, described by Friou, which reacts with intact nuclei. Normal serum was also obtained. The serum was frozen and stored at minus ten degrees centigrade and thawed immediately before use.

#### The Fluorescent Antibody\*

Anti-human globulin was produced by repeated injection of an alum precipitated gamma globulin

\* The fluorescent conjugated antiglobulin was provided by Dr. George J. Friou.



into rabbits. The anti-human globulin was then separated by ammonium sulfate fractionation from the rest of the rabbit serum. Next, the anti-human globulin was conjugated with fluorescein isocyanate II. The procedure used was that of Coons and Kaplan as described in their paper of 1950.<sup>21</sup> The resulting fluorescent rabbit anti-human globulin proved to have a precipitin titre of 1:10 against human globulin.<sup>30</sup>

#### The Staining Procedure

A drop of the chromosome preparation was placed on each of a series of slides. The slides were dried at room temperature for ten minutes at a distance of three feet from an electric fan. After the drying process had been completed, one drop of the thawed lupus erythematosus serum was applied to the dried chromosome precipitate on each slide. Next, the slides were incubated for one half hour at room temperature. To prevent drying during the incubation period these were placed in a covered pan with a moist towel in the bottom. The following step was a washing procedure using phosphate buffer prepared by adding 40 grams of sodium chloride to 6.9 grams of sodium phosphate and mixing with enough distilled water to give a volume of 5000 cc. The pH was



adjusted to 7.0 with 40 per cent NaOH.

After the washing has been completed, the slides were shaken once or twice to remove any excess buffer. One drop of the fluorescent rabbit anti-human globulin conjugate was then applied and the slides incubated for one-half hour again, in the covered pan. The washing procedure was repeated. Then, one drop of a glycerine-phosphate buffer solution (1 ml. of phosphate buffer plus 9 ml. of glycerol) was added to each slide and cover slips applied. The slides were now ready to be examined.

### Results

The chromosomes were seen to readily fluoresce under the ultraviolet microscope (plate 1.). This suggests that a specific complex has been formed in the following sequence: first the chromosomes bind a factor in the gamma globulin fraction of the lupus erythematosus serum, then the fluorescent rabbit anti-human gamma globulin attaches to the gamma globulin. The latter combination is known to be an antigen-antibody reaction.

Two controls were run in order to prove that a specific combination had taken place between some factor in the L.E. serum and the chromosomes.




PLATE I



Chromosome stained with fluorescent antibody.  
Due to the printing process the stain appears blue  
rather than the original green.



10



THE UNIVERSITY OF CHICAGO PRESS  
50 EAST LAKE STREET, CHICAGO, ILL. 60607  
TEL: 773-936-3700 FAX: 773-936-3701

1.) Normal serum was substituted for the L.E. serum in the staining process. No fluorescence was observed.

2.) L.E. serum was absorbed with nucleoprotein in the following manner: calf thymus nucleoprotein was precipitated by adding 170 ml. of .177 M sodium chloride solution to 100 ml. of calf thymus nuclear extract and refrigerating at 40 degrees F. for one-half hour. The precipitate was then washed with .15 M sodium chloride solution and centrifuged. The absorption was accomplished by adding the nucleoprotein precipitate to 5 ml. of L.E. serum and letting the mixture stand at 40 degrees F. One hour later the L.E. serum was decanted and the process repeated with another batch of nucleoprotein precipitate. It was then determined that the absorbed serum did not produce the L.E. phenomenon nor contain the factor which reacts with intact nuclei.<sup>30</sup>

When the absorbed lupus serum was used in the fluorescent staining process with chromosomes no staining took place. This suggests that the material in chromosomes with which the lupus globulin factor reacts is nucleoprotein.

The final step in the investigation confirms the impression that the material in chromosomes



which combines with the lupus serum factor is indeed nucleoprotein. Mirsky and Ris found that chromosomes could be fractionated into two parts by placing them in a neutral solution of 1 M sodium chloride.<sup>29</sup> One fraction, the supernatant fluid, proved to be nucleoprotein. The remaining insoluble precipitate, making up 8 to 10 per cent of the chromosomal mass contained, "12 to 14 per cent ribose nucleic and about one-fifth as much desoxyribose nucleic acid."<sup>29</sup> Following the method of Mirsky and Ris, the chicken erythrocyte chromosomes were fractionated. The supernatant fluid, virtually pure nucleoprotein, was dried on a slide and stained by the fluorescent antibody technique as outlined earlier. The nucleoprotein stained brightly.



Summary

By use of Coons' fluorescent antibody staining technique, it was demonstrated that a serum factor from patients with lupus erythematosus adheres to isolated chromosomes. It was further shown that this is due to a combination between the nucleoprotein of the chromosomes and the factor of the serum.



## BIBLIOGRAPHY

1. Hargraves, M.M; Richmond, H.; and Morton, R.  
Presentation of Two Bone Marrow Elements:  
The "Tart" Cell and the "L.E." Cell, Proc.  
Staff Meet., Mayo Clin. 23:25, Jan. 21, 1948.
2. Goodman, H.L., L.E. Cell Phenomenon; significance  
and reliability. M. Bull. U.S. Army Europe  
9:437-439, Nov. 1952.
3. Lincoln, M., Ricker, W.A. Case of Periarteritis  
Nodosa with L.E. Cells; apparent complete  
remission with cortisone therapy. Ann.  
Int. Med. 41:639-646, Sept. 1954.
4. Walsh, J.R., and Zimmerman, H.S. Demonstration  
of "L.E." Phenomenon in patients with  
penicillin hypersensitivity. Blood 8:65-71,  
Jan. 1953.
5. Miescher, P. and Delacretaz, J. Demonstration of  
positive L.E. phenomenon following hyper-  
sensitivity to penicillin and hydantoin  
therapy; two cases. Schweiz Med. Wchnschr.  
83:536-538, June 6, 1953.
6. Reinhardt, D.J., III, and Waldron, J.M., Lupus  
erythematosus-like syndrome complicating  
hydralazine therapy. JAMA 155:1492-1491,  
Aug. 21, 1954.
7. Haserick, J.R.; Lewis, L.A., and Bortz, D.W.,  
Blood factor in acute disseminated lupus  
erythematosus: I. Determination of gamma  
globulin as specific plasma fraction.  
Am. J. M. Sc. 219:600, 1950.
8. Miescher et Fauconnet, M. Experientia X/6, 252, 1954.
9. Friou, G.J., Finch, S.C., and Detre, K., Nuclear  
Localization of a factor from disseminated  
lupus serum. In process of publication.
10. Personal communication.
11. Haserick, J.R., and Sundberg, R.D, The bone marrow  
as a diagnostic aid in acute disseminated  
lupus erythematosus: Report on the Hargraves  
"L.E." cell, J. Invest. Dermat., 11:209, 1948





12. Haserick, J.R., and Bortz, D.W. Normal bone marrow inclusion phenomenon induced by lupus erythematosus plasma, *J. Invest. Dermat.* 13:47, 1949.
13. Haserick, J.R., and Bortz, D.W. New diagnostic test for acute disseminated lupus erythematosus, *Cleveland Clin. Quart.* 16:158, 1949.
14. Haserick, J.R. Blood factor in acute disseminated lupus erythematosus. *Arch. Dermat. and Syph.* 61:889, 1950.
15. Haserick, J.R., Lewis, L.A. Blood factor in acute disseminated lupus erythematosus: II: Induction of specific antibodies against L.E. factor. *Blood* 5:718, 1950.
16. Hargraves, M.M. Symposium on systemic lupus erythematosus; L.E. cell phenomenon. *Proc. Staff Meet. Mayo Clin.* 27:419-423, Oct. 22, 1952.
17. Reiner, L. *Science*, 72, 483, 1930.
18. Marrack, J. *Nature*, 133, 292, 1934.
19. Coons, A.H., Creech, H., and Jones, N. Immunological properties of an antibody containing a fluorescent group. *Proc. Exper. Biol. and Med.*, 47, 200-202, 1941.
20. Coons, A.H., Creech, H.J., Jones, R.W., and Berliner, E. The demonstration of pneumococcal antigen in tissues by the use of fluorescent antibody. *J. Immunol.*, 45: 159-170, 1942.
21. Coons, A.H., and Kaplan, M.H. Localization of antigen in tissue cells. II. Improvements in a method for the detection of antigen by means of fluorescent antibody. *J. Exper. Med.*, 91:1-13, 1950.
22. Bogert, M.T., and Wright, R.G. *J. Am. Chem. Soc.* 27:1310, 1905.
23. Coons, A.H., Creech, H.J., Jones, R.W., and Berliner, E. *J. Immunol.*, 45:159, 1942.
24. Kaplan, M.<sup>H</sup>, Coons, A.H., and Deane, H.W. Localization of antigen in tissue cells III: Cellular distribution of pneumococcal polysaccharides types II and III in the mouse. *J. Exper. Med.*, 91:15-30, 1950.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

2. The second part of the document outlines the various methods and techniques used to collect and analyze data. It includes a detailed description of the experimental procedures and the tools used for data collection.

3. The third part of the document presents the results of the study, including a comparison of the different methods and techniques used. It discusses the strengths and weaknesses of each method and provides a summary of the findings.

4. The fourth part of the document discusses the implications of the study and provides recommendations for future research. It highlights the need for further investigation into the effectiveness of the different methods and techniques used.

5. The fifth part of the document provides a conclusion and a summary of the key findings. It reiterates the importance of maintaining accurate records and the need for transparency and accountability in financial reporting.

6. The sixth part of the document provides a list of references and a bibliography. It includes a list of all the sources used in the study and provides a detailed description of each source.

7. The seventh part of the document provides a list of appendices and a bibliography. It includes a list of all the appendices used in the study and provides a detailed description of each appendix.

8. The eighth part of the document provides a list of figures and a bibliography. It includes a list of all the figures used in the study and provides a detailed description of each figure.

9. The ninth part of the document provides a list of tables and a bibliography. It includes a list of all the tables used in the study and provides a detailed description of each table.


10. The tenth part of the document provides a list of footnotes and a bibliography. It includes a list of all the footnotes used in the study and provides a detailed description of each footnote.

11. The eleventh part of the document provides a list of references and a bibliography. It includes a list of all the sources used in the study and provides a detailed description of each source.

12. The twelfth part of the document provides a list of appendices and a bibliography. It includes a list of all the appendices used in the study and provides a detailed description of each appendix.

25. Hill, A.G.S., Deane, H.W., and Coons, A.H. Localization of antigen in tissue cells, V. Capsular polysaccharide of Friedlander bacillus, Type B, in the mouse. J. Exper. Med., 92:35-44, 1950.
26. Watson, B.K. Fate of mumps virus in the embryonated egg as determined by specific staining with fluorescein-labeled immune serum. J. Exper. Med., 96:653-663, 1952.
27. Gitlen, D., Landing, B.H., and Whipple, A. The localization of homologous plasma proteins in the tissues of young human beings as demonstrated with fluorescent antibodies. J. Exper. Med., 97:163-176, 1953.
28. Goldman, M. Cytochemical differentiation of *Endamoeba histolytica* and *Endamoeba coli* by means of fluorescent antibody. Am. J. Hyg., 58:319-328, 1953.
29. Mirsky, A.E., and Ris, Hans. Isolated chromosomes. J. of Gen. Physiology 31:1-6, 1947.
30. Friou, G.J. Personal communication.













YALE MEDICAL LIBRARY

Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and deposited in the Yale Medical Library are to be used only with due regard to the rights of the authors. Bibliographical references may be noted, but passages must not be copied without permission of the authors, and without proper credit being given in subsequent written or published work.

This thesis by \_\_\_\_\_ has been used by the following persons, whose signatures attest their acceptance of the above restrictions.

\_\_\_\_\_

NAME AND ADDRESS

DATE

